Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/132743
DC FieldValueLanguage
dc.contributor.authorGalvan Ruiz, Marioen_US
dc.contributor.authorFernández de Sanmamed Girón, M.en_US
dc.contributor.authorDel Val Groba, Marco M.en_US
dc.contributor.authorRojo Jorge, Lorenaen_US
dc.contributor.authorPeña Saavedra, Claudiaen_US
dc.contributor.authorMartín Bou, Elviraen_US
dc.contributor.authorAndrade Guerra, Rubenen_US
dc.contributor.authorCaballero Dorta, Eduardo Joséen_US
dc.contributor.authorGarcía Quintana, Antonioen_US
dc.date.accessioned2024-08-26T12:31:38Z-
dc.date.available2024-08-26T12:31:38Z-
dc.date.issued2024en_US
dc.identifier.issn2055-5822en_US
dc.identifier.otherWoS-
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/132743-
dc.description.abstractAims: The aim of this study was to determine the clinical profile, associated events and safety of vericiguat in a real-world cohort of patients with heart failure with reduced ejection fraction (HFrEF). Methods: This study is a prospective and observational cohort study of patients with HFrEF and recent HF worsening episodes requiring intravenous therapy who initiated vericiguat in an HF outpatient clinic. A subanalysis of patients with >= 6 months' follow-up was performed separately. Results: Out of 103 patients initially included, 52 had a follow-up of at least 6 months (median follow-up of 303 days). At baseline, the mean age was 71.3 +/- 9.4 years, 27.2% were women, the median left ventricular ejection fraction was 34% (28%-39%) and 99% were taking beta-blockers, 96.1% sodium-glucose cotransporter-2 (SGLT2) inhibitors, 95.1% sacubitril-valsartan, 90.3% aldosterone antagonists and 93.2% loop diuretics. During follow-up, New York Heart Association (NYHA) functional class improved (from 67.3% and 32.7% in classes III and II, respectively, to 22.4% and 75.5% at study end; P < 0.001), as did the EuroQol-5D (EQ-5D) and visual analogue scale (VAS) scores (from 0.83 +/- 0.13 to 0.87 +/- 0.12, P = 0.032, and from 60 to 79, P = 0.005, respectively). Vericiguat was well tolerated (13.5% had symptomatic hypotension, and 11.5% had discontinued treatment), and 78.8% of patients achieved the target dose of 10 mg. The number of HF-related hospitalizations/decompensations within the previous 12 months was 2.3 +/- 1.4 and decreased with vericiguat to 0.79 +/- 1.14 (P < 0.001). At study end, 7.7% died (50% for HF). Conclusions: In clinical practice, treatment with vericiguat is associated with substantial improvements in functional class and quality of life and a reduction in hospitalizations for HF, with a low risk of adverse effects.en_US
dc.languageengen_US
dc.relation.ispartofESC heart failureen_US
dc.sourceESC Heart Failure[EISSN 2055-5822], (Enero 2024)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320501 Cardiologíaen_US
dc.subject.otherHeart-Failureen_US
dc.subject.otherHeart Failureen_US
dc.subject.otherHospitalizationen_US
dc.subject.otherVericiguaten_US
dc.titleClinical profile, associated events and safety of vericiguat in a real-world cohort: The VERITA studyen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1002/ehf2.15032en_US
dc.identifier.scopus85201316163-
dc.identifier.isi001292963400001-
dc.contributor.orcid0000-0002-7817-5850-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.authorscopusid57210104862-
dc.contributor.authorscopusid57210110617-
dc.contributor.authorscopusid45961185800-
dc.contributor.authorscopusid59261191300-
dc.contributor.authorscopusid59261548800-
dc.contributor.authorscopusid59260833100-
dc.contributor.authorscopusid59261735200-
dc.contributor.authorscopusid56845776500-
dc.contributor.authorscopusid55985523200-
dc.identifier.eissn2055-5822-
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.description.numberofpages9en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Ruiz, MG-
dc.contributor.wosstandardWOS:Girón, MFD-
dc.contributor.wosstandardWOS:Marco, MDG-
dc.contributor.wosstandardWOS:Jorge, LR-
dc.contributor.wosstandardWOS:Saavedra, CP-
dc.contributor.wosstandardWOS:Bou, EM-
dc.contributor.wosstandardWOS:Guerra, RA-
dc.contributor.wosstandardWOS:Dorta, EC-
dc.contributor.wosstandardWOS:Quintana, AG-
dc.date.coverdateEnero 2024en_US
dc.identifier.ulpgcNoen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,425-
dc.description.jcr3,2-
dc.description.sjrqQ1-
dc.description.jcrqQ2-
dc.description.scieSCIE-
dc.description.miaricds10,3-
item.fulltextCon texto completo-
item.grantfulltextopen-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.fullNameCaballero Dorta, Eduardo José-
Appears in Collections:Artículos
Adobe PDF (392,78 kB)
Show simple item record

SCOPUSTM   
Citations

1
checked on Mar 30, 2025

Page view(s)

33
checked on Jan 11, 2025

Download(s)

77
checked on Jan 11, 2025

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.